Literature DB >> 25136947

Progress in the diagnosis and management of pulmonary hypertension in children.

Jeremy Nicolarsen1, Dunbar Ivy.   

Abstract

PURPOSE OF REVIEW: Pulmonary hypertension is a complex disease that extends beyond merely elevated pulmonary blood pressures and right ventricular dysfunction. Its multiple causes and ever-expanding diagnostic tools and therapeutic approaches make it a heterogeneous disease with widely variable clinical sequelae. There are still many unanswered questions that challenge our understanding of this disease. RECENT
FINDINGS: The study of pulmonary hypertension in the pediatric patient is as robust as ever, with the creation and inclusion of pediatric-specific disease characteristics in the most recent WHO classification system, improved understanding of the pathophysiology of pulmonary hypertension in pediatric diseases such as bronchopulmonary dysplasia, and increasingly expanding diagnostic tools and management possibilities. Although the use of pulmonary hypertension therapies in children previously often relied on expert opinion and inferences from studies involving adults, pediatric-targeted research is becoming more widely supported and pursued, and has even come under recent debate, which at the very least stimulates further collaboration and discussion.
SUMMARY: This review will highlight the changes in the pulmonary hypertension classification system, briefly explore pulmonary hypertension in bronchopulmonary dysplasia, and provide updates on the diagnostic and management tools used by experts in the field.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25136947      PMCID: PMC4225814          DOI: 10.1097/MOP.0000000000000135

Source DB:  PubMed          Journal:  Curr Opin Pediatr        ISSN: 1040-8703            Impact factor:   2.856


  67 in total

1.  Prospective analysis of pulmonary hypertension in extremely low birth weight infants.

Authors:  Ramachandra Bhat; Ariel A Salas; Chris Foster; Waldemar A Carlo; Namasivayam Ambalavanan
Journal:  Pediatrics       Date:  2012-02-06       Impact factor: 7.124

Review 2.  Updated clinical classification of pulmonary hypertension.

Authors:  Gérald Simonneau; Ivan M Robbins; Maurice Beghetti; Richard N Channick; Marion Delcroix; Christopher P Denton; C Gregory Elliott; Sean P Gaine; Mark T Gladwin; Zhi-Cheng Jing; Michael J Krowka; David Langleben; Norifumi Nakanishi; Rogério Souza
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

3.  STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension.

Authors:  Robyn J Barst; Maurice Beghetti; Tomas Pulido; Gary Layton; Irina Konourina; Min Zhang; D Dunbar Ivy
Journal:  Circulation       Date:  2014-03-17       Impact factor: 29.690

4.  Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension.

Authors:  Anna Fijalkowska; Marcin Kurzyna; Adam Torbicki; Grzegorz Szewczyk; Michal Florczyk; Piotr Pruszczyk; Monika Szturmowicz
Journal:  Chest       Date:  2006-05       Impact factor: 9.410

5.  Clinical features of paediatric pulmonary hypertension: a registry study.

Authors:  Rolf M F Berger; Maurice Beghetti; Tilman Humpl; Gary E Raskob; D Dunbar Ivy; Zhi-Cheng Jing; Damien Bonnet; Ingram Schulze-Neick; Robyn J Barst
Journal:  Lancet       Date:  2012-01-11       Impact factor: 79.321

6.  RV stroke work in children with pulmonary arterial hypertension: estimation based on invasive haemodynamic assessment and correlation with outcomes.

Authors:  Michael V Di Maria; Adel K Younoszai; Luc Mertens; Bruce F Landeck; D Dunbar Ivy; Kendall S Hunter; Mark K Friedberg
Journal:  Heart       Date:  2014-04-29       Impact factor: 5.994

7.  Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension.

Authors:  Shinichi Takatsuki; Erika B Rosenzweig; Warren Zuckerman; Daniela Brady; Michelle Calderbank; D Dunbar Ivy
Journal:  Pediatr Pulmonol       Date:  2012-04-17

8.  Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment.

Authors:  J Sandoval; J Gaspar; T Pulido; E Bautista; M L Martínez-Guerra; M Zeballos; A Palomar; A Gómez
Journal:  J Am Coll Cardiol       Date:  1998-08       Impact factor: 24.094

9.  Prognostic value of B-type natriuretic peptide in children with pulmonary hypertension.

Authors:  Astrid E Lammers; Alison A Hislop; Sheila G Haworth
Journal:  Int J Cardiol       Date:  2008-07-02       Impact factor: 4.164

10.  Wall shear stress measured by phase contrast cardiovascular magnetic resonance in children and adolescents with pulmonary arterial hypertension.

Authors:  Uyen Truong; Brian Fonseca; Jamie Dunning; Shawna Burgett; Craig Lanning; D Dunbar Ivy; Robin Shandas; Kendall Hunter; Alex J Barker
Journal:  J Cardiovasc Magn Reson       Date:  2013-09-13       Impact factor: 5.364

View more
  5 in total

1.  A Computable Phenotype Improves Cohort Ascertainment in a Pediatric Pulmonary Hypertension Registry.

Authors:  Alon Geva; Jessica L Gronsbell; Tianxi Cai; Tianrun Cai; Shawn N Murphy; Jessica C Lyons; Michelle M Heinz; Marc D Natter; Nandan Patibandla; Jonathan Bickel; Mary P Mullen; Kenneth D Mandl
Journal:  J Pediatr       Date:  2017-06-16       Impact factor: 4.406

2.  Prevalence of Pulmonary Hypertension in Pediatric Patients With Obstructive Sleep Apnea and a Cardiology Evaluation: A Retrospective Analysis.

Authors:  Antoinette T Burns; Shana L Hansen; Zachary S Turner; James K Aden; Alexander B Black; Daniel P Hsu
Journal:  J Clin Sleep Med       Date:  2019-08-15       Impact factor: 4.062

Review 3.  Useful pharmacodynamic endpoints in children: selection, measurement, and next steps.

Authors:  Lauren E Kelly; Yashwant Sinha; Charlotte I S Barker; Joseph F Standing; Martin Offringa
Journal:  Pediatr Res       Date:  2018-04-18       Impact factor: 3.756

4.  Pediatric Pulmonary Hypertension: Definitions, Mechanisms, Diagnosis, and Treatment.

Authors:  Devashis Mukherjee; Girija G Konduri
Journal:  Compr Physiol       Date:  2021-06-30       Impact factor: 8.915

5.  Development and construct validation of a parent-proxy quality of life instrument in children with bronchopulmonary dysplasia aged 4-8 years old.

Authors:  Lysbert Meijer-Schaap; Anthony E J Dubois; Boudewijn J Kollen; Jet Tijmens-van der Hulst; Bertine M J Flokstra-de Blok; Elianne J L E Vrijlandt
Journal:  Qual Life Res       Date:  2018-10-22       Impact factor: 4.147

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.